Ameriprise Financial Inc. lowered its position in STERIS plc (NYSE:STE - Free Report) by 2.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 190,792 shares of the medical equipment provider's stock after selling 5,669 shares during the quarter. Ameriprise Financial Inc. owned 0.19% of STERIS worth $39,219,000 at the end of the most recent quarter.
A number of other hedge funds have also made changes to their positions in the company. AXA S.A. increased its position in shares of STERIS by 526.1% in the fourth quarter. AXA S.A. now owns 19,628 shares of the medical equipment provider's stock valued at $4,035,000 after buying an additional 16,493 shares in the last quarter. Gallagher Fiduciary Advisors LLC increased its position in shares of STERIS by 3.3% in the fourth quarter. Gallagher Fiduciary Advisors LLC now owns 1,970 shares of the medical equipment provider's stock valued at $405,000 after buying an additional 63 shares in the last quarter. Wahed Invest LLC increased its position in shares of STERIS by 3.2% in the fourth quarter. Wahed Invest LLC now owns 2,469 shares of the medical equipment provider's stock valued at $508,000 after buying an additional 77 shares in the last quarter. Mercer Global Advisors Inc. ADV increased its position in shares of STERIS by 4.4% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 3,756 shares of the medical equipment provider's stock valued at $772,000 after buying an additional 157 shares in the last quarter. Finally, Schonfeld Strategic Advisors LLC increased its position in shares of STERIS by 796.7% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 7,900 shares of the medical equipment provider's stock valued at $1,624,000 after buying an additional 7,019 shares in the last quarter. Hedge funds and other institutional investors own 94.69% of the company's stock.
STERIS Trading Up 2.1%
NYSE:STE traded up $5.24 during mid-day trading on Friday, reaching $252.12. The company's stock had a trading volume of 1,623,045 shares, compared to its average volume of 543,948. The company's fifty day simple moving average is $223.65 and its two-hundred day simple moving average is $219.15. The company has a debt-to-equity ratio of 0.32, a current ratio of 2.13 and a quick ratio of 1.40. STERIS plc has a twelve month low of $200.98 and a twelve month high of $252.20. The stock has a market cap of $24.77 billion, a P/E ratio of 53.53 and a beta of 0.96.
STERIS (NYSE:STE - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The medical equipment provider reported $2.74 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.59 by $0.15. STERIS had a return on equity of 13.91% and a net margin of 8.66%. The firm had revenue of $1.48 billion for the quarter, compared to analyst estimates of $1.47 billion. During the same period last year, the company earned $2.58 EPS. The firm's quarterly revenue was up 5.7% on a year-over-year basis. On average, equities analysts predict that STERIS plc will post 9.08 EPS for the current year.
STERIS Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 26th. Shareholders of record on Tuesday, June 10th will be paid a $0.57 dividend. This represents a $2.28 dividend on an annualized basis and a yield of 0.90%. The ex-dividend date of this dividend is Tuesday, June 10th. STERIS's payout ratio is 36.77%.
Analysts Set New Price Targets
A number of research firms recently commented on STE. JMP Securities lifted their price objective on STERIS from $265.00 to $280.00 and gave the stock a "market outperform" rating in a research report on Friday. Stephens reiterated an "overweight" rating and set a $250.00 price objective on shares of STERIS in a research report on Thursday. Needham & Company LLC reiterated a "hold" rating on shares of STERIS in a research report on Monday, April 7th. Finally, Piper Sandler lifted their price objective on STERIS from $260.00 to $265.00 and gave the stock an "overweight" rating in a research report on Monday, February 3rd. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $265.00.
Read Our Latest Stock Analysis on STERIS
About STERIS
(
Free Report)
STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.
See Also
Before you consider STERIS, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and STERIS wasn't on the list.
While STERIS currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
